Effects of the treatment with acarbose in elderly overweight type 2 diabetic patients in poor glycemic control with oral hypoglycemic agents or insulin

Sangiorgio, L.; Attardo, Tiziana; Condorelli, Luigi; Lunetta, M

doi:10.1016/s0167-4943(00)00064-9

Cited by 5 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, AGIs may increase insulin sensitivity in diabetic elderly patients 117. They are effective in elderly overweight type 2 diabetic patients 118. They are well tolerated in older adults even with multiple comorbidities with a low incidence of hypoglycemia as monotherapy.…”

Section: Options Of Therapy In Elderly Patientsmentioning

confidence: 99%

“…Further, if AGIs are prescribed with prandial insulin, mismatch between peak serum glucose levels and peak prandial insulin levels may occur, placing patients at increased risk for hypoglycemia 71. The most common adverse events are gastrointestinal disturbances, especially flatulence, abdominal distension, diarrhea, abdominal pain, and abdominal discomfort, which preclude AGIs application in the elderly patients 118,120–123. The clinical response of AGIs depends on preserved β-cell function.…”

Section: Options Of Therapy In Elderly Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options

Du¹,

Ou²,

Beverly³

et al. 2014

CIA

View full text Add to dashboard Cite

The prevalence of type 2 diabetes mellitus (T2DM) is increasing in the elderly. Because of the unique characteristics of elderly people with T2DM, therapeutic strategy and focus should be tailored to suit this population. This article reviews the guidelines and studies related to older people with T2DM worldwide. A few important themes are generalized: 1) the functional and cognitive status is critical for older people with T2DM considering their life expectancy compared to younger counterparts; 2) both severe hypoglycemia and persistent hyperglycemia are deleterious to older adults with T2DM, and both conditions should be avoided when determining therapeutic goals; 3) recently developed guidelines emphasize the avoidance of hypoglycemic episodes in older people, even in the absence of symptoms. In addition, we raise the concern of glycemic variability, and discuss the rationale for the selection of current options in managing this patient population.

show abstract

Section: Options Of Therapy In Elderly Patientsmentioning

confidence: 99%

Section: Options Of Therapy In Elderly Patientsmentioning

confidence: 99%

Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options

Du¹,

Ou²,

Beverly³

et al. 2014

CIA

View full text Add to dashboard Cite

show abstract

“…Because insulin, SU and TZDs often induce weight gain, diabetologists may hesitate to select these drugs as first choice for the treatment of type 2 diabetic patients with obesity. On the other hand, αGI and BG do not usually induce weight gain [1][2][3][4][5][6]; therefore, they are considered as first line treatment for obese patients. In fact, the United Kingdom Prospective Diabetes Study (UKPDS) demonstrated the usefulness of acarbose (αGI) [7] and metformin (BG) [8] in treating type 2 diabetic patients with obesity.…”

Section: Introductionmentioning

confidence: 99%

"Low Dose" Metformin Improves Hyperglycemia Better Than Acarbose in Type 2 Diabetics

Yajima

Shimada²,

Hara³

et al. 2004

Rev Diab Stud

View full text Add to dashboard Cite

■ AbstractOBJECTIVES: "High dose" metformin therapy (2,550 mg/day) is reported to improve glycemic control in type 2 diabetic patients with obesity (body mass index (BMI) ≥ 30). Some have reported that metformin therapy, even in low doses (500-750 mg/day), improves glycemic control in nonobese type 2 diabetic patients (BMI approximately 25). However, it is unclear whether "low dose" metformin improves glycemic control better than acarbose in non-obese type 2 diabetic patients, which has been shown to improve glycemic control in type 2 diabetes with obesity. METH-ODS: We randomly divided 22 non-obese type 2 diabetic patients (mean BMI approximately 25) into two groups (A = 11, B = 11). Group A was treated with "low dose" metformin (500-750 mg/day) for 3 months, and switched to acarbose (150-300 mg/day) for another 3 months. Group B was treated with acarbose first, and then switched to "low dose" metformin. RESULTS: "Low dose" metformin significantly decreased the fasting plasma glucose (FPG) and HbA1c level in both groups A and B, whereas acarbose decreased HbA1c levels in group B but not in group A. Overall, "low dose" metformin significantly decreased HbA1c (p = 0.0165) levels as compared to acarbose. CON-CLUSION: In conclusion, "low dose" metformin therapy improved glycemic control better than acarbose in nonobese diabetics.

show abstract

Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control

Vos

Avendonk

Jansen

et al. 2016

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Effects of the treatment with acarbose in elderly overweight type 2 diabetic patients in poor glycemic control with oral hypoglycemic agents or insulin

Cited by 5 publications

References 19 publications

Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options

Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options

"Low Dose" Metformin Improves Hyperglycemia Better Than Acarbose in Type 2 Diabetics

Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control

Contact Info

Product

Resources

About